HANSOH PHARMAC. HD-00001 - Asset Resilience Ratio
HANSOH PHARMAC. HD-00001 (3KY) has an Asset Resilience Ratio of 0.04% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of HANSOH PHARMAC. HD-00001 for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how HANSOH PHARMAC. HD-00001's Asset Resilience Ratio has changed over time. See free cash flow generation of HANSOH PHARMAC. HD-00001 to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down HANSOH PHARMAC. HD-00001's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see HANSOH PHARMAC. HD-00001 total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €17.61 Million | 0.04% |
| Total Liquid Assets | €17.61 Million | 0.04% |
Asset Resilience Insights
- Limited Liquidity: HANSOH PHARMAC. HD-00001 maintains only 0.04% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
HANSOH PHARMAC. HD-00001 Industry Peers by Asset Resilience Ratio
Compare HANSOH PHARMAC. HD-00001's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangxi Synergy Pharmaceutical Co Ltd
SHE:300636 |
Drug Manufacturers - Specialty & Generic | 4.68% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 9.44% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Shandong Shanda Wit Science and Technology Co Ltd
SHE:000915 |
Drug Manufacturers - Specialty & Generic | 25.22% |
|
Jiangsu Jibeier Pharmaceutical Co Ltd
SHG:688566 |
Drug Manufacturers - Specialty & Generic | 2.98% |
Annual Asset Resilience Ratio for HANSOH PHARMAC. HD-00001 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for HANSOH PHARMAC. HD-00001.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.04% | €17.61 Million ≈ $20.59 Million |
€39.90 Billion ≈ $46.65 Billion |
-2.37pp |
| 2024-12-31 | 2.42% | €764.71 Million ≈ $894.02 Million |
€31.66 Billion ≈ $37.01 Billion |
-4.92pp |
| 2023-12-31 | 7.33% | €2.42 Billion ≈ $2.83 Billion |
€33.04 Billion ≈ $38.63 Billion |
-6.03pp |
| 2022-12-31 | 13.36% | €4.01 Billion ≈ $4.69 Billion |
€30.00 Billion ≈ $35.08 Billion |
-2.22pp |
| 2021-12-31 | 15.58% | €4.23 Billion ≈ $4.95 Billion |
€27.16 Billion ≈ $31.75 Billion |
-- |
About HANSOH PHARMAC. HD-00001
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products … Read more